The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...
“This will significantly modernise IPF’s Brisbane PDC capability, enabling us to meet our customers’ expectations well into the future. “The decision to relocate the PDC allows us to progress our ...
Walker announced earlier in the month that he was retiring from radio after 58 years due to ill health, having been previously diagnosed with idiopathic pulmonary fibrosis (IPF). After playing Johnny ...